PMID- 29719460
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 1226-8453 (Print)
IS  - 2093-4947 (Electronic)
IS  - 1226-8453 (Linking)
VI  - 42
IP  - 2
DP  - 2018 Apr
TI  - Korean Red Ginseng exhibits no significant adverse effect on disease activity in 
      patients with rheumatoid arthritis: a randomized, double-blind, crossover study.
PG  - 144-148
LID - 10.1016/j.jgr.2017.01.006 [doi]
AB  - BACKGROUND: Panax ginseng is a well-known immune modulator, and there is concern 
      that its immune-enhancing effects may negatively affect patients with rheumatoid 
      arthritis (RA) by worsening symptoms or increasing the risk of adverse effects 
      from other drugs. In this randomized, crossover clinical trial, we evaluated the 
      impact of Korean Red Ginseng (KRG) on disease activity and safety in RA patients. 
      METHODS: A total of 80 female RA patients were randomly assigned to either the 
      KRG (2 g/d, n = 40) treatment or placebo (n = 40) groups for 8 wk, followed by 
      crossover to the other treatment group for an additional 8 wk. The primary 
      outcome was the disease flare rate, defined as worsening disease activity 
      according to the disease activity score 28 joints-erythrocyte sedimentation rate 
      (DAS28-ESR). The secondary outcomes were development of adverse events (AEs) and 
      patient reported outcomes. Outcomes were evaluated at baseline and 8 wk and 16 
      wk. The outcomes were compared using the Chi-square test. RESULTS: Of the 80 
      patients, 70 completed the full study. Their mean age was 51.9 yr, and most 
      exhibited low disease activity (mean DAS28-ESR 3.5 +/- 1.0) at enrollment. After 
      intervention, the flare rate was 3.7% in each group. During KRG treatment, 10 AEs 
      were reported, while five AEs were developed with placebo; however, this 
      difference was not statistically significant (p = 0.16). Gastrointestinal- and 
      nervous system-related symptoms were frequent in the KRG group. CONCLUSION: KRG 
      is not significantly associated with either disease flare rate or the rate of AE 
      development in RA patients.
FAU - Cho, Soo-Kyung
AU  - Cho SK
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Kim, Dam
AU  - Kim D
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Yoo, Dasomi
AU  - Yoo D
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Jang, Eun Jin
AU  - Jang EJ
AD  - Department of Information Statistics, Andong National University, Andong-si, 
      Republic of Korea.
FAU - Jun, Jae-Bum
AU  - Jun JB
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Sung, Yoon-Kyoung
AU  - Sung YK
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20170120
PL  - Korea (South)
TA  - J Ginseng Res
JT  - Journal of ginseng research
JID - 100890690
PMC - PMC5925614
OTO - NOTNLM
OT  - Korean Red Ginseng
OT  - effect
OT  - rheumatoid arthritis
OT  - safety
EDAT- 2018/05/03 06:00
MHDA- 2018/05/03 06:01
PMCR- 2017/01/20
CRDT- 2018/05/03 06:00
PHST- 2016/10/01 00:00 [received]
PHST- 2016/12/13 00:00 [revised]
PHST- 2017/01/13 00:00 [accepted]
PHST- 2018/05/03 06:00 [entrez]
PHST- 2018/05/03 06:00 [pubmed]
PHST- 2018/05/03 06:01 [medline]
PHST- 2017/01/20 00:00 [pmc-release]
AID - S1226-8453(16)30215-9 [pii]
AID - 10.1016/j.jgr.2017.01.006 [doi]
PST - ppublish
SO  - J Ginseng Res. 2018 Apr;42(2):144-148. doi: 10.1016/j.jgr.2017.01.006. Epub 2017 
      Jan 20.